Masahiro Sakane - Takeda Pharmaceutical Independent Chairman of the Executive Board
Chairman
Mr. Masahiro Sakane was serving as Independent Chairman of the Executive Board in Takeda Pharmaceutical Company Limited since June 2017. He is also serving as Independent Director in KAJIMA CORPORATION, and working for Komatsu Ltd. since 2017.
| Age | 79 |
| Tenure | 8 years |
| Phone | 81 3 3278-2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0251 % which means that on every $100 spent on assets, it made $0.0251 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0294 %, implying that it generated $0.0294 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.03. The value of Return On Capital Employed is expected to slide to 0.02. Total Current Liabilities is expected to rise to about 2.8 T this year. Liabilities And Stockholders Equity is expected to rise to about 18.2 T this yearTakeda Pharmaceutical Co has 4.84 T in debt with debt to equity (D/E) ratio of 0.81, which is OK given its current industry classification. Takeda Pharmaceutical has a current ratio of 1.16, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Takeda to invest in growth at high rates of return.
Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| David Stack | Pacira BioSciences, | 75 | |
| RPh Pharm | Collegium Pharmaceutical | 61 | |
| Ronald Lombardi | Prestige Brand Holdings | 60 | |
| Ronald CPA | Prestige Brand Holdings | 61 | |
| Jack Bendheim | Phibro Animal Health | 78 | |
Management Performance
| Return On Equity | 0.0294 | ||||
| Return On Asset | 0.0251 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Giles Platford, President Unit | ||
| Ian Clark, Independent Director | ||
| Constantine Saroukos, CFO Director | ||
| Salvatore MD, Member Policy | ||
| Milano Furuta, Chief Officer | ||
| Masami Iijima, Independent Director | ||
| Christophe Weber, President, Chief Executive Officer, Representative Director | ||
| Masahiro Sakane, Independent Chairman of the Executive Board | ||
| Seigo Izumo, Chair Board | ||
| Olivier Bohuon, Independent Director | ||
| Gabriele Ricci, Chief Officer | ||
| Ken Araki, Vice Department | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Senior Department | ||
| Michel Orsinger, Independent Director | ||
| Shiro Kuniya, Independent Director | ||
| Christopher OReilly, Global Finance | ||
| Toshiyuki Shiga, Independent Director | ||
| Steven Gillis, Independent Director | ||
| Mwana Lugogo, Chief Officer | ||
| Lauren Duprey, Chief Officer | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, President of Japan Pharma Business Unit, Director | ||
| Emiko Higashi, Independent Director | ||
| Andrew Plump, President of Research & Development, Vice President of Subsidiary, Director | ||
| Costa Saroukos, Chief Financial Officer, Director | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yoshihiro Nakagawa, Global Counsel |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0294 | ||||
| Return On Asset | 0.0251 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 76.82 B | ||||
| Shares Outstanding | 3.16 B | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.32 % | ||||
| Number Of Shares Shorted | 4.31 M | ||||
| Price To Earning | 27.57 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Tools for Takeda Stock
When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |